Invitae Corporation (NYSE:NVTA), backed by SoftBank Group (OTC:SFTBY) (OTC:SFTBF), is reportedly on the brink of filing for bankruptcy in the coming weeks. The San Francisco-based medical genetics ...
Shares of Invitae are trading for less than a nickel apiece after a report surfaced earlier this week claiming the genetic testing company is on the verge of filing for bankruptcy. The report came ...
Invitae (NYSE: NVTA) has grown revenue over time, but the genetic testing specialist has failed to turn that into profit. Instead, the company burned through more and more cash, prompting it to launch ...
Mutations to the BRCA1 and BRCA2 genes significantly increase the chances of breast and ovarian cancers, and a test can assess a person’s risk from those variants. But those genes are just two of the ...
Invitae (NYSE: NVTA) has been one of the most beaten-up stocks this year, falling more than 70% thus far (the S&P 500 has declined by only 10% over the same period). Significant losses and a growth ...
The company will offer up to 12.8 million shares of common stock that could fetch up to $57.5 million in gross proceeds. Today, Invitae announced that each share will be offered at $4.50, which is ...
Invitae’s (NVTA) significant revenue growth in its most recently reported quarter and its success in bringing customized health monitoring into the mainstream have heightened investor optimism around ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results